Kromek Group (LSE: KMK) sits at the crossroads of homeland security and advanced medical imaging. It’s small, volatile, and easy to overlook — but recent order momentum is putting it back on the market’s radar.
Valuation snapshot
Share price (early trade)
~9–10p
Market cap (approx.)
~£63m
6-month move (approx.)
~+80%
Broker target (avg. est.)
26p
Note: Penny stocks can move sharply on modest volume. Consider position sizing and risk tolerance before acting.
At first glance, Kromek Group looks like the kind of AIM-listed name most investors scroll past. It trades in pennies, carries a modest market value, and rarely features in mainstream UK defence coverage dominated by bigger players. Yet the business sits in a niche with growing demand: radiation and bio-detection technology for national security, civil nuclear markets, and advanced medical imaging.
What Kromek actually does
Kromek develops and supplies radiation detection components and solutions used across security, healthcare, and industrial applications. It’s known for compact, high-performance detectors capable of identifying gamma radiation and neutrons — the kind of capability used to protect urban environments and critical infrastructure from radiological threats.
For investors, the key point is that this is not a “single theme” business. Defence and homeland security are one growth driver, but medical imaging and industrial applications provide another potential revenue stream — which can matter when government procurement cycles slow.
Defence momentum is showing up in the numbers
The recent move in the shares hasn’t come from nowhere. In the six months to the end of October 2025, sales in the company’s chemical, biological, radiological, and nuclear defence (CBRN) division more than doubled to £4.3m. That performance reflects a broader shift: heightened national security focus is translating into real procurement demand, not just headlines.
In its half-year update published in January, Kromek also said that in the current year to date, it had received new CBRN detection orders worth £4.8m, spanning customers across the UK, Europe, the US, Japan, Canada, and Australasia. For a company around the £60m mark in market value, contract wins of that scale can shift sentiment quickly.
Not just defence: medical imaging can change the profile
Kromek’s other key exposure is advanced imaging for healthcare and industry, including detectors used in SPECT scanning. The company has highlighted that recent revenues in this division have been helped by a major commercial relationship with Siemens Healthineers, where Kromek supplies cadmium zinc telluride (CZT) detectors.
The strategic appeal is straightforward: if the healthcare side gains scale, it can provide a steadier counterbalance to the lumpy, contract-driven nature of defence procurement. That doesn’t eliminate risk — but it can improve revenue quality over time.
Why analysts see big upside — and why caution still matters
The headline attraction is the gap between where the shares trade and where brokers think they could go. With an average target around 26p, the implied upside is substantial — but penny stock maths cuts both ways. Small disappointments can cause large percentage swings, especially when liquidity is thin.
You May Also Like
Rolls-Royce Share Price Today: RYCEY Hits an Early 52-Week High
The latest early-session move, key levels to watch, and what’s driving the momentum right now.
For investors doing deeper research, the practical questions are simple: do CBRN orders keep arriving, do deliveries convert cleanly into revenue, and does the medical imaging story develop into a steadier second engine? If the answers trend positively, the valuation debate can shift quickly in a small-cap name like this.
For broader context on the UK’s approach to security preparedness and related policy framing, the Home Office is a useful starting point.
Editorial note: This article is for information only and is not financial advice. Penny stocks can be highly volatile and may not suit all investors.
